Furthermore, analysis of microarray data on human breast tumors showed that breast cancer patients with DLX2 expression had on average better prognosis and less incidence of relapse, while DLX5 expression and DLX2 downregulation, was related to a subset of more aggressive tumors. Here, DLX5 is linked to breast neoplasm.